Categories: NewsPharmaceutical

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

Staff

Recent Posts

Hear at Last Signs a Canada Wide Distribution with Hohm Pods for Portable Home Pods

Toronto, Ontario--(Newsfile Corp. - November 7, 2024) - HearAtLast Holdings, Inc. (OTC Pink: HRAL), is…

1 hour ago

Vitaquest Hires David Alcaraz as Senior Vice President, Quality Assurance

Alcaraz brings nearly 20 years of experience in quality management to the roleWest Caldwell, New…

2 hours ago

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market

Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024Vancouver, British Columbia and…

2 hours ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

2 hours ago

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

2 hours ago

Ludwig Enterprises Begins PCR Validation Test Process

Final step before the full launch of breast cancer screening program, Revealia™SPARKS, NV / ACCESSWIRE…

2 hours ago